Aptose Biosciences
Corporate Headquarters
251 Consumers Road
Suite 1105
Toronto
Ontario
M2J 4R3
Canada
Website: http://aptose.com/
146 articles with Aptose Biosciences
-
Aptose To Release Third Quarter Ended September 30, 2017 Financial Results and Hold Conference Call on November 14, 2017
11/7/2017
The company intends to host a conference call the same day at 5:00 p.m. ET to discuss the financial results.
-
Aptose Enters Into $15.5M Common Shares Purchase Agreement With Aspire Capital Fund
10/30/2017
Aptose also provided a corporate update on the development of its two hematology drug candidates.
-
Aptose Biosciences And CrystalGenomics Announce Issuance Of U.S. Patent For CG’806
9/12/2017
-
Aptose Biosciences Reports Results For The Second Quarter Ended June 30, 2017
8/9/2017
-
Aptose Biosciences To Release Second Quarter Ended June 30, 2017 Financial Results And Hold Conference Call On August 8, 2017
8/1/2017
-
Aptose Biosciences Announces Results Of Annual Meeting Of Shareholders
6/7/2017
-
Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2017
5/12/2017
-
Preclinical Data On Aptose Biosciences FLT3/BTK Inhibitor CG’806 Presented At AACR Hematologic Malignancies Meeting
5/8/2017
-
Oregon Health & Science University (OHSU) And Aptose Biosciences Present CG’806 Preclinical Data Demonstrating Potent Activity Against Patient Samples At AACR Hematologic Malignancies Meeting
5/8/2017
-
Aptose Biosciences To Release First Quarter Ended March 31, 2017 Financial Results And Hold Conference Call On May 11, 2017
4/24/2017
-
Aptose Biosciences Provides Update On Apto-253 Development
12/29/2016
-
Aptose Biosciences And CrystalGenomics Announce Exclusive Agreement For Non-Covalent BTK / FLT3 / AURK Inhibitor
6/8/2016
-
Aptose Biosciences Reports Results For The First Quarter Ended March 31, 2016
5/11/2016
-
Aptose Biosciences To Participate In Upcoming Investor Conferences
3/4/2016
-
H. Lee Moffitt Cancer Center & Research Institute And Aptose Biosciences To Present Data On A Novel Class Of Dual-Targeting Bromodomain / Kinase Inhibitors At 57th Annual American Society of Hematology Meeting
12/3/2015
-
Aptose Biosciences To Participate In Upcoming Investor Conferences
12/1/2015
-
Aptose Biosciences Suspends Dosing of Lead Drug APTO-253
11/20/2015
-
Aptose Biosciences Reports Results For The Third Quarter Ended September 30, 2015
11/11/2015
-
Aptose Biosciences Announces Collaborations For New Multi-Targeting Epigenetic Therapeutic Agents
11/10/2015
-
Beat AML & Aptose Biosciences Present Data For APTO-253 At The 57th American Society of Hematology Annual Meeting
11/5/2015